Amyloid-Related Imaging Abnormalities in Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer’s Disease: Expert Recommendation for Standard MRI Protocol
The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi ®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings,...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Radiology
2025-01-01
|
| Series: | Journal of the Korean Society of Radiology |
| Subjects: | |
| Online Access: | https://doi.org/10.3348/jksr.2024.0147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The introduction of anti-amyloid therapies for Alzheimer’s disease (AD), such as lecanemab (Lequembi
®), which was recently approved in Korea, necessitates careful monitoring for amyloid-related imaging
abnormalities (ARIA) using brain MRI. To optimize ARIA monitoring in Korean clinical settings, the
Korean Society of Neuroradiology (KSNR) and the Age and Neurodegeneration Imaging (ANDI) Study
Group proposed MRI protocol recommendations on essential MR sequences, MRI acquisition parameters,
timing and condition of MRI examinations, and essential details to provide a scientific basis for
maximizing the safety and efficacy of AD treatment. A customized, standardized MRI protocol focusing
on Korea’s healthcare environment can improve ARIA management and ensure patient safety through
early detection of potential anti-amyloid therapy side effects, thereby enhancing treatment quality. |
|---|---|
| ISSN: | 2951-0805 |